Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Industry Strategies for NASH Combination Therapieswww.linkedin.com/pulse/industry-strat...
NASH drugs come into focus as field awaits late-stage datawww.biopharmadive.com/news/nash-drugs...
De enige interessante is Viking.
Is Viking Therapeutics the Best NASH Stock to Buy Now?www.fool.com/investing/2018/09/20/is-...
No liver safety issues (ALT decrease!) and 67% (!) of pts >50% reduction in liver fat. Homerun for $VKTX!mobile.twitter.com/DavidBautz/status/...
Viking Therapeutics upgraded to Strong Buy at Raymond James As previously reported, Raymond James upgraded Viking Therapeutics (VKTX) to Strong Buy from Outperform with a $43 price target. Following AASLD, Analyst Steven Seedhouse thinks TR-B remains one of the most promising mechanisms with proof-of-concept in NASH based on VK2809 and MGL-3196 data presented and conversations with physicians. The analyst expects increased comfort with Viking's path to market as we approach several catalysts including a long-term animal toxicology study completion, IND filing/acceptance, and Phase 2b start. Seedhouse also expects the M&A premium in Madrigal Pharmaceuticals (MDGL) to shift to Viking, which has a more attractive valuation if there is a rush on NASH assets. Read more at: thefly.com/landingPageNews.php?id=282...
Genfit gaat voor een IPO in de VS. Koers +6%.
Lingus schreef op 19 november 2018 14:43 :
Genfit gaat voor een IPO in de VS. Koers +6%.
Genfit is een misfit.
DeZwarteRidder schreef op 19 november 2018 14:57 :
[...]
Genfit is een misfit.
Boeiend verhaal. Lekker kort ook.
2019 wordt een belangrijk jaar voor de Nash bedrijven. Intercept zal Q1 als eerste zijn fase 3 resultaten presenteren, de koers is al flink opgelopen de laatste maanden (evenals de shorts overigens). Daarnaast wordt verwacht dat Gilead stappen zal ondernemen om zijn programma uit te breiden, hun eigen onderzoek heeft niet echt tot goede kandidaten geleid die de markt kunnen overvallen. Mijn geld staat op Intercept en Viking, ookal loopt Viking ze ietsje achter op Madrigal en Intercept. Tot op heden lijkt hun product 'best in class' te worden en zijn ze nog relatief goed geprijsd. Ik ben benieuwd hoe het ervoor staat als Gilead zich gaat bewegen op de markt en als er meer resultaten binnen komen.
Viking biedt de meeste kansen op succes en is een geheide overnamekandidaat.
Zoals verwacht, vannacht het persbericht van Gilead: www.investors.com/news/technology/gil... Gild faalt hard in onderzoek naar een potentiële kandidaat tegen NASH. Viking, Madrigal en Intercept stijgen voorbeurs goed door. Nu is de vraag; wat gaat Gilead doen. Slaan ze toe via een overname? Zo ja; wie van de 3? Of verlaten ze het NASH speelveld en lijven ze wellicht Galapagos in.. Gilead zal iets moeten doen om de aandeelhouders tevreden te houden, bijna ieder zelf ontwikkeld medicijn is geflopt na hun grootste kaskraker tegen HIV.
Hoe denken jullie over Inventiva? Kleine speler op NASH gebied. Hun middel Lanifibranor bevind zich momenteel in fase 2. Het aandeel is de afgelopen dagen flink gestegen
2019, THE NASH LANDSCAPE Feb 2019 , what is the updated NASH landscape? www.nashbiotechs.com/nash-biotech-ana...
News Release Issued: Apr 11, 2019 (7:02am EDT) SAN DIEGO, April 11, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the company's 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C) at the International Liver Congress™ 2019. The study results were presented in the late-breaker poster session of the annual meeting of the European Association for the Study of the Liver (EASL), being held April 10-14 in Vienna, Austria. Highlights from the late-breaker poster include newly reported data demonstrating that all patients who received 5 mg of VK2809 dosed daily were considered responders, as defined by a relative reduction in liver fat of = 30% at Week 12. Patients in the VK2809 5 mg cohort also experienced a statistically significant median relative reduction in liver fat content of 53.8%. Consistent with the observations from the 10 mg cohorts in this study, VK2809 was shown to be safe and well tolerated when dosed at 5 mg daily, with no serious adverse events reported. Overall, a greater proportion of VK2809-treated patients completed the study compared with patients randomized to placebo.
Intercept NASH data vallen tegen? Koers duikelt 11% onderuit
Wil Helmus schreef op 11 april 2019 16:26 :
Intercept NASH data vallen tegen? Koers duikelt 11% onderuit
Dat is geen wonder.
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna.
EASL 2019 – Novo buys into Gilead’s Nash combo plan Today’s deal will see the companies take a triple combination into clinical trials. The diabetes specialist Novo Nordisk has already worked in Nash, so today’s clinical trial alliance with Gilead marks another baby step towards developing a treatment. The tie-up is noteworthy for other reasons, too, marking another buy-in to the theory that Nash needs to be treated with a combinatorial approach, and underlining its link with diabetes. But could this mean that existing diabetes drugs could be used for Nash? And what happens to the bull thesis that Gilead is on the lookout for acquisition targets in this liver disease? The buyout thesis has helped keep Nash enthusiasm going despite two late-stage setbacks this year, one of which involved Gilead's own selonsertib. However, Gilead striking small, clinical trial tie-ups suggests a far more cautious attitude from a company that many think needs to do M&A, though of course this does not entirely rule out future acquisitions. A little air escaped the Nash bubble yesterday, largely as a result of Intercept’s underwhelming data at the EASL conference, and even Viking, which presented a promising update for VK2809, ended the day down 2% (EASL 2019 – Viking to push the limits of its Nash contender, April 11, 2019). Three-way tie The Gilead/Novo tie-up will see the former’s cilofexor and firsocostat combined with the latter’s semaglutide, a GLP-1 analogue marketed for diabetes. Nash followers will be familiar with all three approaches. The Gilead compounds are already being combined, and a 20-subject proof-of-concept trial presented at EASLshowed that 74% had at least a 30% fall in liver fat, as measured by MRI-PDFF, from baseline after 12 weeks. Novo has an ongoing phase II trial of semaglutide monotherapy in Nash. And liraglutide, another Novo GLP-1 analogue diabetes drug, has already yielded impressive monotherapy results, showing Nash resolution in 39% subjects, versus 9% for placebo, in a small study. This is a threat to novel Nash projects. However, the fact that the Danish group has now seen the need to put semaglutide into a combo should give some comfort to those fearing the worst. It is thought that Nash, diabetes and obesity are related, but a developing school of thought holds that a combined approach is needed to affect fat metabolism and reduce fibrosis. Intercept, for instance, licensed Aralez’s PPAR agonist bezafibrate to combine with Ocaliva, though this was also driven by a need to broaden the latter’s therapeutic window. NN9499 FGF 21 analogue Novo NordiskObesity project with Nash potential It will not go unnoticed that PPAR agonism is also used to treat diabetes. Yet another player, Cymabay, is developing the PPAR delta agonist seladelpar for Nash, and one of its EASL presentations today concerned preclinical results of a combo with either Gilead's selonsertib, an Ask-1 inhibitor, or with liraglutide. Selonsertib appeared to show little additive effect on top of seladelpar, and notably the former was not part of today’s Novo deal with Gilead. But adding the GLP-1 to seladelpar caused a much greater reduction in liver fat than using either agent alone. “GLP-1 receptor agonists are increasingly being recognised as having significant potential for the treatment of Nash,” Charles McWherter, Cymabay’s chief scientific officer, told Vantage today at EASL. “When used in combination, they may represent an opportunity to take novel agents into Nash patients with earlier stages of fibrosis.” Pfizer, another GLP-1 player, agrees. “If we can induce significant weight loss we can have a positive impact on [Nash],” said Roberto Calle, a director in Pfizer’s internal medicine research unit. “And the GLP-1s have been proven to do that.” One consideration is that a monotherapy approval might be needed before any combination of the novel agents can hit the market. This, along with Gilead’s caution, could act as a further brake on the bull case for Nash.www.evaluate.com/node/14580/amp
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
870,27
-0,43%
EUR/USD
1,0736
+0,36%
FTSE 100
8.078,86
+0,48%
Germany40^
17.907,20
-1,00%
Gold spot
2.330,08
+0,60%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers